Barclays Maintains Overweight on Sempra, Lowers Price Target to $90
Barclays analyst Nicholas Campanella maintains Sempra (NYSE:SRE) with a Overweight and lowers the price target from $103 to $90.
Share
Why It Matters
A big bank analyst still likes Sempra but thinks the stock might be worth less money soon. You can watch if other experts agree or disagree with this new price guess.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.